Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Eleclazine in Renal Impairment
NCT02441829Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- May 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of eleclazine in long QT syndrome (LQTS) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at 57 days and Maximum Observed Plasma Concentration at 57 days. Started May 2015; status: completed.
02
Drugs
eleclazine
03
Conditions
long QT syndrome (LQTS)
Beyond the preview
Go deeper on NCT02441829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441829.